Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167358 · ClinicalTrials.gov registry record · Phase 3
Linerixibat Long-term Safety, and Tolerability Study
A Phase 3 study of Cholestasis, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
- 20
- Study locations
NCT04167358 is a Phase 3 study of Cholestasis that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 242 participants, above the 117-participant average among 6 other Cholestasis trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04167358, a Phase 3 study of Cholestasis, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 \[NCT01899703\], 201000 GLIMMER \[NCT02966834\] (group 1) or 212620 GLISTEN \[NCT00210418\]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants. However, the total duration of study participation will vary by participant depending upon the time of entry relative to study end in their respective country.
Conditions Studied
Interventions
- DRUG Linerixibat
Study Locations (20)
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Capital Federal
- GSK Investigational Site - Ciudad AutOnoma de Buenos Aire
- GSK Investigational Site - Ciudad Autonoma de Bueno
- GSK Investigational Site - Rosario
- GSK Investigational Site - Santa Fe
- GSK Investigational Site - Botucatu
- GSK Investigational Site - Brasília
California
- GSK Investigational Site - Davis
- GSK Investigational Site - West Hollywood
North Carolina
- GSK Investigational Site - Durham
- GSK Investigational Site - Morrisville
Texas
- GSK Investigational Site - Dallas
- GSK Investigational Site - Houston
Florida
- GSK Investigational Site - Miami
Michigan
- GSK Investigational Site - Detroit
New York
- GSK Investigational Site - New York
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167358
The ClinicalTrials.gov registry entry for NCT04167358 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 117-participant average among 6 other Cholestasis trials with a reported enrollment target (107% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cholestasis appearing as the primary indexed condition, and to 1 intervention - of which Linerixibat is the first listed.
NCT04167358 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04167358 about?
NCT04167358 is a clinical study titled "Linerixibat Long-term Safety, and Tolerability Study". This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 \[NCT0189970...
What is the current status of trial NCT04167358?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2020-07-14. Estimated completion is 2026-09-30.
What conditions does trial NCT04167358 study?
This clinical trial studies the following conditions: Cholestasis.
What interventions are being tested in trial NCT04167358?
The interventions under investigation include: Linerixibat (DRUG).
Who is sponsoring clinical trial NCT04167358?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04167358 being conducted?
This trial has 20 study locations across California, Florida, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholestasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
COMPLETED · Phase 3
-
Gabapentin to Treat Itch in Patients With Liver Disease
COMPLETED · Phase 3
-
Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease
ACTIVE NOT RECRUITING
-
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
COMPLETED · NA
-
Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
COMPLETED · NA
-
Cholestasis Prevention: Efficacy of IV Fish Oil
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.